158 related articles for article (PubMed ID: 30012535)
21. Erratum to: Lee AW, Ng WT, Pan JJ, et al. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys 2019;105:567-580.
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1166-1167. PubMed ID: 31748141
[No Abstract] [Full Text] [Related]
22. Erratum to: Käsmann L, Manapov F. Immune Checkpoint Inhibition Combined With Intracranial Stereotactic Radiation Therapy in Non-Small Cell Lung Cancer: Is There an Increased Rate of Radionecrosis or Not? Int J Radiat Oncol Biol Phys 2018;102:465.
Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):286. PubMed ID: 30563663
[No Abstract] [Full Text] [Related]
23. Response to "Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation" (Int J Radiat Oncol Biol Phys 2010;76:71-78) and "Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation" Int J Radiat Oncol Biol Phys 2009;75:1290-1296).
Wolmark N; Curran WJ; Vicini F; White J; Costantino JP; Arthur D; Kuske R; Rabinovitch R; Julian TB; Parda DS
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):317; author reply 318. PubMed ID: 20394863
[No Abstract] [Full Text] [Related]
24. Response to "Stereotactic ablative radiotherapy in the framework of classical radiobiology: response to Drs. Brown, Diehn, and Loo." (Int J Radiat Oncol Biol Phys 2011;79:1599-1600) and "Influence of tumor hypoxia on stereotactic ablative radiotherapy (SABR): response to Drs. Mayer and Timmerman." (Int J Radiation Oncol Biol Phys 2011;78:1600).
Song CW; Levitt SH; Park H
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1193; author reply 1193-4. PubMed ID: 22036162
[No Abstract] [Full Text] [Related]
25. Erratum to: Woodward WA, Fang P, Arriaga L, et al. A phase 2 study of preoperative capecitabine and concomitant radiation in women with advanced breast cancer. Int J Radiat Oncol Biol Phys 2017;99:777-783.
Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):497. PubMed ID: 29726371
[No Abstract] [Full Text] [Related]
26. What is the target volume for preoperative accelerated partial breast irradiation (APBI)? In regards to Nichols et al. (Int J Radiat Oncol Biol Phys 2010;77:197-202) and Palta et al. (Int J Radiat Oncol Biol Phys 2010, in Press).
Kim L; Shaitelman S
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):314-5; author reply 315-6. PubMed ID: 21481727
[No Abstract] [Full Text] [Related]
27. Erratum to: Ho AY, Olm-Shipman M, Zhang Z, et al. A Randomized Trial of Mometasone Furoate 0.1% to Reduce High Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation. Int J Radiat Oncol Biol Phys 2018;101;325-333.
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):231. PubMed ID: 30102200
[No Abstract] [Full Text] [Related]
28. Erratum to: Hafeez S, McDonald F, Lalondrelle S, et al. Clinical outcomes of image guided adaptive hypofractionated weekly radiation therapy for bladder cancer in patients unsuitable for radical treatment. Int J Radiat Oncol Biol Phys 2017;98:115-122.
Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):532-533. PubMed ID: 29353666
[No Abstract] [Full Text] [Related]
29. Erratum to: Zhongjie Chen, Yinshan Fang, Si Zhang, et al. Haplodeletion of Follistatin-Like 1 Attenuates Radiation-Induced Pulmonary Fibrosis in Mice. Int J Radiat Oncol Biol Phys 2019;103:208-216.
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(4):890. PubMed ID: 32092348
[No Abstract] [Full Text] [Related]
30. Erratum to: Kirova YM, Loap P, Fourquet A. Benefit of Post Mastectomy Radiation Therapy (PMRT) in Node-Positive, HER2-Positive Patients With Breast Cancer Receiving Anti-HER2 Treatments. Int J Radiat Oncol Biol Phys 2020;106:511-513.
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(3):606-607. PubMed ID: 32531392
[No Abstract] [Full Text] [Related]
31. Erratum to: Gunther JR, Jimenez RB, Yechieli RL, et al. Introductory Radiation Oncology Curriculum: Report of a National Needs Assessment and Multi-institutional Pilot Implementation. Int J Radiat Oncol Biol Phys 2018;101:1029-1038.
Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1602. PubMed ID: 31014796
[No Abstract] [Full Text] [Related]
32. Erratum to: Nguyen PL. Rethinking the Balance of Risk and Benefit of Androgen Deprivation Therapy for Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2016;94:975-977.
Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1549. PubMed ID: 27479731
[No Abstract] [Full Text] [Related]
33. Erratum to: Hypofractionated Radiation Therapy Combined With Weekly Chemotherapy in Patients With Unresectable or Recurrent Thymic Epithelial Tumor: A Prospective, Single-Arm Phase 2 Study (GASTO-1042). Int J Radiat Oncol Biol Phys. 2022 Sep 1;114(1):89-98.
Chu Chu ; Liang Y; Lin X; Liu Y; Liu S; Guo J; Wang D; Wang J; Liu H; Qiu B
Int J Radiat Oncol Biol Phys; 2023 Mar; 115(4):1014. PubMed ID: 36822779
[No Abstract] [Full Text] [Related]
34. Erratum to: Hao Y, Ran Y, Lu B, et al. Therapeutic Effects of Human Umbilical Cord-derived Mesenchymal Stem Cells on Canine Radiation-Induced Lung Injury. Int J Radiat Oncol Biol Phys 2018;102:407-416.
Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):287. PubMed ID: 30563665
[No Abstract] [Full Text] [Related]
35. Erratum to: Reddy J, Lei X, Bloom S, et al. Optimizing Preventive Adjuvant Linac-Based (OPAL) Radiation: A Phase 2 Trial of Daily Partial Breast Irradiation. Int J Radiat Oncol Biol Phys 2024;115(3): 629-644.
Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):1034. PubMed ID: 38851265
[No Abstract] [Full Text] [Related]
36. Erratum to: Kong X-T, Nguyen NT, Choi YJ, et al. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. Int J Radiat Oncol Biol Phys 2018;100:1195-1203.
Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1289. PubMed ID: 30900570
[No Abstract] [Full Text] [Related]
37. Erratum to: Blitzblau RC, Horton JK. First, Do No Harm. Int J Radiat Oncol Biol Phys 2019;103:295-296.
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):701. PubMed ID: 30928359
[No Abstract] [Full Text] [Related]
38. Erratum to: Wallner PE, Anscher MS, Barker CA, et al. Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary. Int J Radiat Oncol Biol Phys 2014;88:11-17.
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1115. PubMed ID: 25832710
[No Abstract] [Full Text] [Related]
39. Erratum to Ringash J, Fisher R, Peters L, et al. Effect of p16 status on the quality-of-life experience during chemoradiation for locally advanced oropharyngeal cancer: a substudy of randomized trial trans-Tasman radiation oncology group (TROG) 02.02 (HeadSTART). Int J Radiat Oncol Biol Phys 2017;97:678-686.
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):244. PubMed ID: 28816156
[No Abstract] [Full Text] [Related]
40. Erratum to: Comparison of Adjuvant Versus Salvage Radiotherapy Policies for Postprostatectomy Radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:329-340.
Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):471. PubMed ID: 30191883
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
